A retrospective cohort study suggested that colchicine prophylaxis at urate-lowering therapy initiation may lower cardiovascular event risk in patients with gout.
This respiratory health update covers rising influenza deaths, the spread of new SARS-CoV-2 variants, shifting reinfection patterns, and cardiovascular risks in children
A randomized clinical trial found that a nurse-led intervention strategy could improve systolic blood pressure and non-high-density lipoprotein cholesterol in patients with HIV, reducing their risk of...
On March 8, the FDA approved the injectable weight loss medication, semaglutide, for reducing the risk of cardiovascular events such as heart attack, stroke, and cardiovascular death in adults with heart...
In a prospective cohort study, researchers found associations between cardiovascular disease risk factors and the development of musculoskeletal disorders.
Did you get the chance to view our Multidisciplinary Roundtable on some hot topics in treating patients with HIV? Here are some highlights that you may have missed.
To better understand the relationship between cardiovascular disease and liver disease in individuals with HIV, researchers examined both traditional risk factors and HIV-specific risk factors of the...
This COVID-19 roundup includes coverage of the FDA’s amendment to its emergency use authorization of the Pfizer-BioNTech booster for pediatric patients, acute myocardial infection deaths rose during omicron...
